Dr. Ehsan Malek, M.D
Medical Oncology (Medical Oncology Physician)
- Medicare participating
At a glance
- Years since graduation
- 22
- In the NPI registry since
- 2009
- Medicare patients seen, 2024
- 32
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2009Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
OH license 35.099890
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Roswell PArk Cancer Institute (488 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 32
- Services billed
- 68
- Patients’ average age
- 66
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 53 | 39 |
| Established patient office or other outpatient visit, 30-39 minutes | 27 | 23 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Payments from drug and device companies
In 2025, 6 companies reported 12 payments worth $18,592 in total to this clinician.
| Menarini Silicon Biosystems, Inc. | $6,435 |
|---|---|
| Adaptive Biotechnologies Corporation | $5,800 |
| Legend Biotech USA Inc. | $3,152 |
| Janssen Scientific Affairs, LLC | $2,300 |
| Regeneron Healthcare Solutions, Inc. | $794 |
| Novartis Pharmaceuticals Corporation | $111 |
| Consulting Fee | $11,164 |
|---|---|
| Honoraria | $6,000 |
| Compensation for services other than consulting (speaking, faculty) | $794 |
| Travel and Lodging | $413 |
| Food and Beverage | $222 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Menarini Silicon Biosystems, Inc. Jan 14, 2025 | Honoraria Cellsearch · Diagnostics | $6,000 |
| Adaptive Biotechnologies Corporation Sep 11, 2025 | Consulting Fee clonoSEQ · Devices | $3,600 |
| Legend Biotech USA Inc. Dec 18, 2025 | Consulting Fee CARVYKTI · Oncology | $3,064 |
| Janssen Scientific Affairs, LLC Jul 30, 2025 | Consulting Fee | $2,300 |
| Adaptive Biotechnologies Corporation Jun 25, 2025 | Consulting Fee clonoSEQ · Devices | $1,600 |
| Regeneron Healthcare Solutions, Inc. Nov 21, 2025 | Compensation for services other than consulting (speaking, faculty) LYNOZYFIC · HEMATOLOGY AND ONCOLOGY | $794 |
| Adaptive Biotechnologies Corporation Sep 4, 2025 | Consulting Fee clonoSEQ · Devices | $600 |
| Menarini Silicon Biosystems, Inc. Jan 14, 2025 | Travel and Lodging Cellsearch · Diagnostics · travel to Milan, Italy | $413 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 2 companies. The companies reported $76,384 in research payments for these studies, mostly to the institutions running them.
- A Phase 1, Multicenter, Open-label Study to Evaluate the Safety and Preliminary Efficacy of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants with Relapsed and/or Refractory Multiple Myeloma …
Celgene Corporation - A Phase 2, Open-Label, Multicenter Study of Arlocabtagene Autoleucel (BMS-986393), a GPRC5D-directed CAR T Cell Therapy in Adult Participants with Relapsed or Refractory Multiple Myeloma (QUINTESSENTIAL)
E.r. Squibb & Sons, L.l.c. - A Phase 1, Multicenter, Open-label Study to Evaluate the Safety and Preliminary Efficacy of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants with Relapsed and/or Refractory Multiple Myeloma …
E.r. Squibb & Sons, L.l.c. - A Phase 2, Open-Label, Multicenter Study of Arlocabtagene Autoleucel (BMS-986393), a GPRC5D-directed CAR T Cell Therapy in Adult Participants with Relapsed or Refractory Multiple Myeloma (QUINTESSENTIAL)
Celgene Corporation
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.